As of 2026-09-08, the EV/EBITDA ratio of Flexion Therapeutics Inc (FLXN) is -7.14. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. FLXN's latest enterprise value is 559.09 mil USD. FLXN's TTM EBITDA according to its financial statements is -78.25 mil USD. Dividing these 2 quantities gives us the above FLXN EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 10.6x - 15.6x | 13.0x |
| Forward P/E multiples | 14.4x - 19.5x | 17.4x |
| Fair Price | (69.14) - (74.11) | (72.54) |
| Upside | -378.9% - -398.9% | -392.6% |
| Date | EV/EBITDA |
| 2026-09-04 | -7.15 |
| 2026-09-03 | -7.15 |
| 2026-09-02 | -7.14 |
| 2026-09-01 | -7.13 |
| 2026-08-31 | -7.15 |
| 2026-08-28 | -7.15 |
| 2026-08-27 | -7.16 |
| 2026-08-26 | -7.16 |
| 2026-08-25 | -7.19 |
| 2026-08-24 | -7.18 |
| 2026-08-21 | -7.18 |
| 2026-08-20 | -7.17 |
| 2026-08-19 | -7.18 |
| 2026-08-18 | -7.16 |
| 2026-08-17 | -7.17 |
| 2026-08-14 | -7.18 |
| 2026-08-13 | -7.19 |
| 2026-08-12 | -7.17 |
| 2026-08-11 | -7.17 |
| 2026-08-10 | -7.16 |
| 2026-08-07 | -7.17 |
| 2026-08-06 | -7.16 |
| 2026-08-05 | -7.16 |
| 2026-08-04 | -7.17 |
| 2026-08-03 | -7.15 |
| 2026-07-31 | -7.13 |
| 2026-07-30 | -7.12 |
| 2026-07-29 | -7.08 |
| 2026-07-28 | -7.11 |
| 2026-07-27 | -7.10 |
| 2026-07-24 | -7.14 |
| 2026-07-23 | -7.14 |
| 2026-07-22 | -7.16 |
| 2026-07-21 | -7.18 |
| 2026-07-20 | -7.18 |
| 2026-07-17 | -7.18 |
| 2026-07-16 | -7.19 |
| 2026-07-15 | -7.20 |
| 2026-07-14 | -7.18 |
| 2026-07-13 | -7.17 |
| 2026-07-10 | -7.19 |
| 2026-07-09 | -7.19 |
| 2026-07-08 | -7.18 |
| 2026-07-07 | -7.19 |
| 2026-07-06 | -7.19 |
| 2026-07-02 | -7.18 |
| 2026-07-01 | -7.18 |
| 2026-06-30 | -7.17 |
| 2026-06-29 | -7.17 |
| 2026-06-26 | -7.20 |